NewcelX (NCEL) vs Palatin Technologies (PTN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Palatin Technologies (PTN) has outperformed NewcelX (NCEL) over the past year, gaining 25.3% versus a loss of 83.3%. Over five years, PTN leads with a -98.3% price change compared with -99.7% for NCEL. NewcelX is the larger company by market cap ($18.0 million vs $16.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NCEL | PTN |
|---|---|---|
| Share price | $3.11 | $9.01 |
| Market cap | $17.96M | $16.05M |
| 1-day change | +2.47% | -5.36% |
| YTD return | +63.68% | -41.42% |
| 1-year return | -83.32% | +25.31% |
| 5-year return | -99.68% | -98.32% |
| P/E ratio (TTM) | 5.98 | — |
| EPS (TTM) | $0.52 | $-2.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.60 | $31.00 |
| 52-week low | $1.83 | $5.61 |
| Distance from 52-week high | -83.28% | -70.94% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +639.55% | +493.78% |
| Average volume | 10.28K | 62.48K |
| Shares outstanding | 5.78M | 1.78M |
| Employees | 9 | 25 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTN has outperformed NCEL by 108.6 percentage points over the past year.
About NewcelX
NCEL stock →NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders.
Healthcare · Biotechnology · 9 employees
About Palatin Technologies
PTN stock →Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases.
Healthcare · Biotechnology · 25 employees
NCEL vs PTN FAQ
Which is bigger, NewcelX or Palatin Technologies?
NewcelX (NCEL) is larger, with a market capitalization of $17.96M compared with $16.05M for Palatin Technologies (PTN).
Which stock has performed better over the past year, NCEL or PTN?
PTN returned +25.31% over the past 12 months, compared with -83.32% for NCEL (price return, excluding dividends). Past performance does not predict future results.
Are NewcelX and Palatin Technologies in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.